NZ730092A - Use of cysteamine in treating infections caused by yeasts/moulds - Google Patents

Use of cysteamine in treating infections caused by yeasts/moulds

Info

Publication number
NZ730092A
NZ730092A NZ730092A NZ73009215A NZ730092A NZ 730092 A NZ730092 A NZ 730092A NZ 730092 A NZ730092 A NZ 730092A NZ 73009215 A NZ73009215 A NZ 73009215A NZ 730092 A NZ730092 A NZ 730092A
Authority
NZ
New Zealand
Prior art keywords
cysteamine
yeasts
moulds
infections caused
treating infections
Prior art date
Application number
NZ730092A
Other languages
English (en)
Inventor
Vanessa Duncan
Deborah O’Neil
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of NZ730092A publication Critical patent/NZ730092A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ730092A 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds NZ730092A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053523P 2014-09-22 2014-09-22
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Publications (1)

Publication Number Publication Date
NZ730092A true NZ730092A (en) 2018-05-25

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ730092A NZ730092A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Country Status (14)

Country Link
EP (1) EP3197476A1 (ja)
JP (1) JP2017532317A (ja)
KR (1) KR20170052613A (ja)
CN (1) CN106687140A (ja)
AU (1) AU2015323566B2 (ja)
BR (1) BR112017005272A2 (ja)
CA (1) CA2959003A1 (ja)
GB (1) GB201416727D0 (ja)
MX (1) MX2017003550A (ja)
NZ (1) NZ730092A (ja)
RU (1) RU2017108196A (ja)
SG (1) SG11201701648UA (ja)
WO (1) WO2016046524A1 (ja)
ZA (1) ZA201701330B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000202A (es) 2015-07-02 2018-06-27 Horizon Orphan Llc Analogos de cisteamina resistentes a la ado y sus usos.
JP2020505359A (ja) * 2017-01-25 2020-02-20 アデア ファーマシューティカルズ，インコーポレイテッド システアミンプロドラッグ
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
EP3866775A1 (en) * 2018-10-17 2021-08-25 Novabiotics Limited Dosage regime
CN110551637B (zh) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 一种来自黄芪根部的高效抑制番茄灰霉病菌的棘壳孢菌及其应用
CN110859950B (zh) * 2019-11-25 2021-08-10 武汉大学 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
ATE479704T1 (de) * 2004-08-18 2010-09-15 Novabiotics Ltd Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
JP2006347990A (ja) * 2005-06-20 2006-12-28 Pola Chem Ind Inc 爪用の抗真菌医薬組成物
JP2006347989A (ja) * 2005-06-20 2006-12-28 Pola Chem Ind Inc 爪用の抗真菌医薬組成物
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EP2464334A4 (en) * 2009-08-13 2014-03-26 Moberg Derma Ab COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTION OF NAILS
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
MX2017003550A (es) 2017-07-28
KR20170052613A (ko) 2017-05-12
EP3197476A1 (en) 2017-08-02
CA2959003A1 (en) 2016-03-31
WO2016046524A1 (en) 2016-03-31
JP2017532317A (ja) 2017-11-02
AU2015323566B2 (en) 2018-03-22
AU2015323566A1 (en) 2017-04-06
RU2017108196A3 (ja) 2019-06-19
GB201416727D0 (en) 2014-11-05
RU2017108196A (ru) 2018-10-24
BR112017005272A2 (pt) 2017-12-12
SG11201701648UA (en) 2017-04-27
CN106687140A (zh) 2017-05-17
ZA201701330B (en) 2018-04-25

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
PH12016501763A1 (en) Multispecific antibodies
IL279627A (en) A method for treating depression
SG11201705093UA (en) Composition for treating il-6-related diseases
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
EA201791110A1 (ru) Сублингвальное введение рилузола
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX2017007188A (es) Compuesto antimicotico.
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
EP3099304A4 (en) Novel therapeutics for the treatment of glaucoma
PL3145511T3 (pl) Kompozycja do leczenia oka
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
EP3136840A4 (en) Aided delivery of plant treatment agents
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
EP3200749A4 (en) Methods for the treatment of peri-implantitis
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
GB2571647B (en) The use of dipropylene/diethylene glycol dibenzoate to reduce eye irritation
IN2014CH01391A (ja)
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
IL251040A0 (en) Using cysteamine to treat infections caused by yeasts/molds
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
GB201521802D0 (en) Mould treatment
IN2014CH00872A (ja)
GB201410990D0 (en) General cure to diseases
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed